Aerovate Therapeutics(US:AVTE)2026-01-05 12:17Financial Projections - As of December 31, 2025, Jade Biosciences, Inc. expects to report approximately $336 million in cash, cash equivalents, and investments, which is projected to fund operations into the first half of 2028[4]. - The company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2025, and the reported cash figure is preliminary and subject to change[5]. - The company has not provided specific revenue or earnings guidance in this report[4]. - Jade's independent registered public accounting firm has not audited the preliminary cash figures, and no assurance is provided regarding their accuracy[5]. Corporate Governance - Jade Biosciences is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards[3]. - The company plans to provide updates on its corporate presentation through its website and will not file a Form 8-K for each update[7]. Clinical Trials and Product Development - Forward-looking statements include expectations regarding the clinical trials for product candidates JADE101, JADE201, and JADE301, with timelines for interim data and trial initiation[11]. - Risks associated with the clinical trials include potential delays, adverse events, and the need for regulatory approvals, which may impact the company's product development[11]. - Jade's product candidates are anticipated to have potential therapeutic uses and may become best-in-class therapies, although actual results may vary[11]. Upcoming Events - The company is preparing for the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12–15, 2026[7].